title: [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
abstract: The use of intravenous immunoglobulin (IVIG) has become an accepted treatment for patients with Guillain-Barré syndrome. Few patients develop adverse reactions to IVIG such as flushing, urticaria, eczema, chest tightness, wheezing, diaphoresis and hypotension. We report three patients who each received a five day course of IVIG at the standard dose of 0.4 g/kg/day. Two patients had Guillain-Barré syndrome, and the other had Miller Fisher syndrome. All developed eczematous reactions after 4 days from the start day of therapy to 5 days from the last day of therapy. One patient with GBS had widespread eczematous eruption with severe pompholyx lesions on the palms, fingers and soles, and spread over a period of 2 to 3 weeks to become generalized. That persisted for 4 weeks but gradually settled with desquamation by the use of topical steroids. None of our patients subsequently developed long-term or chronic eczema after the resolution of the initial cutaneous reaction. Eczematous reactions of our patients were similar to those reported in the literature and clinically typical as pompholyx. Although pompholyx has been recognized as a clinical entity, its cause remains obscure. Cutaneous reactions after IVIG infusion are recognized to be rare, but actually they may occur more frequently than our recognition, and its knowledge is essential to make the right clinical decision.
authors.affiliation: Department of Neurology, Akita Red Cross Hospital, Akita, Japan.
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Tada
authors.forename: Mari
authors.initials: M
authors.lastname: Tada
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Eiichi
authors.initials: E
authors.lastname: Yagi
authors.forename: Kouichi
authors.initials: K
authors.lastname: Hirota
mesh_terms: D000328:Adult; D011146:Eczema, Dyshidrotic / Q000209:etiology*; D020275:Guillain-Barre Syndrome / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D019846:Miller Fisher Syndrome / Q000628:therapy*; D014581:Urticaria / Q000209:etiology
chemical_list: D016756:Immunoglobulins, Intravenous